Sarah W.
- Country
- France
- Department
- Medical Oncology
Research Overview
- PREDOSTAR - PREventing second cancers with DOSTARlimab - A multicenter, open-label, randomized phase II study aiming to assess the clinical impact of dostarlimab on occurrence of second primary cancer in patients with cured primary cancer
- Phase IIb/III Randomized Controlled Study of Lurbinectedin Plus Doxorubicin Versus Doxorubicin Monotherapy in Metastatic Leiomyosarcoma Patients
- Phase III Study on Molecular Profiling and Drug Combination Therapy in Advanced Unresectable Soft-Tissue Sarcoma Using Futibatinib, Durvalumab, and Olaparib
Data & Insights
Has run more than one trial at 22 of 75 partner sites.
Specializations
Sarcoma Research
The investigator specializes in treating various forms of sarcomas, with particular emphasis on advanced soft tissue sarcomas and their molecular characterization.
- Undifferentiated Pleomorphic Sarcoma
- Retroperitoneal Sarcomas
- Leiomyosarcoma
- Endometrial Stromal Sarcoma
Research extends to both localized and metastatic disease presentations.
Therapeutic Innovations
The investigator focuses on evaluating novel therapeutic approaches including immunotherapy combinations and targeted treatments.
- Pembrolizumab-Cabozantinib Combination
- Retifanlimab Applications
- Dostarlimab Treatment
- Mipasetamab Uzoptirine Therapy
Expertise includes neoadjuvant and systemic treatment strategies.
Cancer Prevention
The investigator studies preventive approaches for second primary cancers in cancer survivors.
- Post-Treatment Cancer Prevention
- Risk Assessment Strategies
- Molecular Profiling Applications
- Treatment Optimization Studies
Focus includes long-term patient outcomes and surveillance protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.